Zymeworks (ZYME) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $25.75, +3.96% vs the prior close of $24.77.
- Volume 751.90K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ZYME jumps 4.0% to $25.75. Closed at $25.75, +3.96% vs the prior close of $24.77. Day range $25.18–$26.21, opened at $25.19.
ZYME daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — ZYME jumps 4.0% to $25.75
- Closed at $25.75, +3.96% vs the prior close of $24.77. Day range $25.18–$26.21, opened at $25.19.
- Volume was 751.90K shares, 0.9x its 50-day average of 883.03K.
- Price is -3.6% vs its 50-day average ($26.71) and +2.8% vs its 200-day average ($25.05).
- 52-week range $16.00–$31.34; today's close sits at 64% of that range, 17.8% below the 52-week high.
Oct 14, 2026 — ZYME dips 1.2% to $24.77, a 1-month low, 3 down days in a row
- Closed at $24.77, -1.20% vs the prior close of $25.07. Day range $24.60–$25.20, opened at $25.00.
- Volume was 558.80K shares, 0.6x its 50-day average of 880.25K.
- Price is -7.1% vs its 50-day average ($26.66) and -1.2% vs its 200-day average ($25.06).
- 52-week range $16.00–$31.34; today's close sits at 57% of that range, 21.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — ZYME dips 1.0% to $25.07, a 1-month low on 2.9x normal volume
- Closed at $25.07, -1.03% vs the prior close of $25.33. Day range $24.92–$25.60, opened at $25.04.
- Volume was 2.46M shares, 2.9x its 50-day average of 839.11K — unusually heavy trading.
- Price is -5.8% vs its 50-day average ($26.62) and +0.0% vs its 200-day average ($25.07).
- 52-week range $16.00–$31.34; today's close sits at 59% of that range, 20.0% below the 52-week high.
Oct 12, 2026 — ZYME dips 1.8% to $25.33 on 3.5x normal volume
- Closed at $25.33, -1.78% vs the prior close of $25.79. Day range $25.19–$25.79, opened at $25.56.
- Volume was 2.78M shares, 3.5x its 50-day average of 791.09K — unusually heavy trading.
- Price is -4.6% vs its 50-day average ($26.56) and +1.0% vs its 200-day average ($25.08).
- 52-week range $16.00–$31.34; today's close sits at 61% of that range, 19.2% below the 52-week high.
Oct 9, 2026 — ZYME rises 2.1% to $25.79
- Closed at $25.79, +2.10% vs the prior close of $25.26. Day range $25.28–$26.34, opened at $25.28.
- Volume was 491.10K shares, 0.6x its 50-day average of 789.33K.
- Price is -2.6% vs its 50-day average ($26.49) and +2.8% vs its 200-day average ($25.09).
- 52-week range $16.00–$31.34; today's close sits at 64% of that range, 17.7% below the 52-week high.
Oct 8, 2026 — ZYME slides 4.8% to $25.26
- Closed at $25.26, -4.79% vs the prior close of $26.53. Day range $25.00–$26.24, opened at $26.24.
- Volume was 1.37M shares, 1.8x its 50-day average of 768.80K.
- Price is -4.4% vs its 50-day average ($26.43) and +0.7% vs its 200-day average ($25.09).
- 52-week range $16.00–$31.34; today's close sits at 60% of that range, 19.4% below the 52-week high.
Oct 7, 2026 — ZYME jumps 3.4% to $26.53 on 2.2x normal volume
- Closed at $26.53, +3.43% vs the prior close of $25.65. Day range $25.17–$27.02, opened at $25.75.
- Volume was 1.62M shares, 2.2x its 50-day average of 743.55K — unusually heavy trading.
- Price is +0.6% vs its 50-day average ($26.36) and +5.7% vs its 200-day average ($25.10).
- 52-week range $16.00–$31.34; today's close sits at 69% of that range, 15.3% below the 52-week high.
Oct 6, 2026 — ZYME dips 2.1% to $25.65 on 2.0x normal volume
- Closed at $25.65, -2.14% vs the prior close of $26.21. Day range $25.51–$26.79, opened at $26.42.
- Volume was 1.47M shares, 2.0x its 50-day average of 719.41K — unusually heavy trading.
- Price is -2.4% vs its 50-day average ($26.29) and +2.2% vs its 200-day average ($25.10).
- 52-week range $16.00–$31.34; today's close sits at 63% of that range, 18.2% below the 52-week high.
Oct 5, 2026 — ZYME jumps 4.2% to $26.21
- Closed at $26.21, +4.21% vs the prior close of $25.15. Day range $25.28–$26.50, opened at $25.37.
- Volume was 1.04M shares, 1.5x its 50-day average of 704.12K.
- Price is -0.1% vs its 50-day average ($26.23) and +4.4% vs its 200-day average ($25.10).
- 52-week range $16.00–$31.34; today's close sits at 67% of that range, 16.4% below the 52-week high.
Oct 2, 2026 — ZYME slides 3.1% to $25.15, a 1-month low, 3 down days in a row
- Closed at $25.15, -3.12% vs the prior close of $25.96. Day range $25.04–$26.19, opened at $26.18.
- Volume was 844.40K shares, 1.2x its 50-day average of 694.39K.
- Price is -3.9% vs its 50-day average ($26.17) and +0.2% vs its 200-day average ($25.10).
- 52-week range $16.00–$31.34; today's close sits at 60% of that range, 19.8% below the 52-week high.
- That makes 3 straight losses.
ZYME latest news & SEC filings
Every SEC filing by or about ZYME in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Schayowitz Adam converted options/RSUs into 37,037 shares on Oct 9, 2026; now holds 37,037
- Schayowitz Adam sold 13,832 shares at $25.85 (≈$357.56K) on Oct 9, 2026; now holds 23,205
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 9, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Aug 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $4.59M (prior year $48.73M) (-90.6% vs Jun 30, 2025)
- Net income: -$45.02M (prior year $2.32M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.62 (prior year $0.03) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 6, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade ZYME
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 2, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.29% (largest 4.8%).
- Liquidity: about 1.14M shares (≈$29.30M) trade per day on average.
- 52-week position: $25.75 vs a range of $16.00–$31.34 (64% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 10 sales; latest: Mark Hollywood sold 6,120 shares on Jan 12, 2026.
- Latest filings: 8-K Sep 23, 2026; 8-K Aug 25, 2026; 10-Q Aug 6, 2026.
- Share count: 70.96M shares outstanding (Aug 4, 2026), -5.6% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
ZYME market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 25.19 | 26.21 | 25.18 | 25.75 | 751.90K |
| Oct 14, 2026 | 25.00 | 25.20 | 24.60 | 24.77 | 558.80K |
| Oct 13, 2026 | 25.04 | 25.60 | 24.92 | 25.07 | 2.46M |
| Oct 12, 2026 | 25.56 | 25.79 | 25.19 | 25.33 | 2.78M |
| Oct 9, 2026 | 25.28 | 26.34 | 25.28 | 25.79 | 491.10K |
| Oct 8, 2026 | 26.24 | 26.24 | 25.00 | 25.26 | 1.37M |
| Oct 7, 2026 | 25.75 | 27.02 | 25.17 | 26.53 | 1.62M |
| Oct 6, 2026 | 26.42 | 26.79 | 25.51 | 25.65 | 1.47M |
| Oct 5, 2026 | 25.37 | 26.50 | 25.28 | 26.21 | 1.04M |
| Oct 2, 2026 | 26.18 | 26.19 | 25.04 | 25.15 | 844.40K |
| Oct 1, 2026 | 26.44 | 26.56 | 25.88 | 25.96 | 808.70K |
| Sep 30, 2026 | 27.25 | 27.73 | 26.47 | 26.49 | 1.58M |
| Sep 29, 2026 | 27.12 | 28.26 | 26.76 | 27.20 | 999.90K |
| Sep 28, 2026 | 25.94 | 27.54 | 25.66 | 27.12 | 1.38M |
| Sep 25, 2026 | 26.86 | 26.88 | 26.23 | 26.52 | 1.09M |
| Sep 24, 2026 | 27.13 | 27.50 | 26.14 | 26.81 | 752.90K |
| Sep 23, 2026 | 27.55 | 27.89 | 26.52 | 27.50 | 647.70K |
| Sep 22, 2026 | 26.72 | 27.70 | 26.55 | 27.57 | 446.00K |
| Sep 21, 2026 | 26.84 | 27.17 | 26.19 | 26.81 | 582.60K |
| Sep 18, 2026 | 27.45 | 27.55 | 26.38 | 26.57 | 1.10M |
About Zymeworks
Zymeworks (ZYME) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in MIDDLETOWN, DE. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1937653.
ZYME board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Carlos Campoy | Director | Jan 12, 2026 |
| Alessandra Cesano | Director | Jan 12, 2026 |
| Brian N Cherry | Director | Jan 13, 2026 |
| Gregory Austin Ciongoli | Director | Jan 12, 2026 |
| Kenneth Galbraith | Chair & CEO | Jan 12, 2026 |
| Robert E Landry | Director | Jan 12, 2026 |
| Susan Mahony | Director | Jan 12, 2026 |
| Kelvin Neu | Director | Jan 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kenneth Galbraith | Chair & CEO | Jan 12, 2026 |
| Mark Hollywood | EVP & Chief Operating Officer | Jul 6, 2026 |
| Sabeen Mekan | SVP & Chief Medical Officer | Feb 2, 2026 |
| Paul Andrew Moore | Chief Scientific Officer | Jan 12, 2026 |
| Leone D Patterson | EVP, Chief Bus & Fin Officer | Jan 7, 2026 |
| Scott Platshon | EVP, Chief Business Officer | Apr 10, 2026 |
| Adam Schayowitz | See Remarks | Apr 10, 2026 |
| Paul R Schneider | EVP, General Counsel | May 15, 2026 |
| Jeffrey T L Smith | EVP & Chief Medical Officer | Jan 12, 2026 |
| Kristin Stafford | EVP, Chief Financial Officer | Apr 7, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jan 12, 2026 | Mark Hollywood | Sale | 6,120 | $22.67 |
| Jan 12, 2026 | Paul Andrew Moore | Sale | 9,560 | $22.67 |
| Jan 12, 2026 | Kenneth Galbraith | Sale | 30,424 | $22.67 |
| Jan 12, 2026 | Jeffrey T L Smith | Sale | 9,310 | $22.67 |
| Jan 5, 2026 | Kenneth Galbraith | Sale | 31,686 | $25.10 |
| Jan 5, 2026 | Kenneth Galbraith | Sale | 22,657 | $25.10 |
| Jan 5, 2026 | Paul Andrew Moore | Sale | 10,821 | $25.10 |
| Jan 5, 2026 | Paul Andrew Moore | Sale | 9,289 | $25.10 |
| Jan 5, 2026 | Jeffrey T L Smith | Sale | 10,538 | $25.10 |
| Dec 22, 2025 | Kenneth Galbraith | Sale | 47,528 | $27.02 |
ZYME financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $105.97M | $-81.13M | -1.08 | $-33.01M |
| Dec 31, 2024 | $76.30M | $-122.69M | -1.62 | $-110.06M |
| Dec 31, 2023 | $76.01M | $-118.67M | -1.72 | $-118.32M |
| Dec 31, 2022 | $412.48M | $124.34M | 1.90 | $144.11M |
| Dec 31, 2021 | $26.68M | $-211.84M | -4.61 | $-192.45M |
Latest balance sheet: total assets $396.96M, total liabilities $316.60M, cash $179.41M (as of Jun 30, 2026).
ZYME earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $23.13 |
| May 7, 2026 | 8-K Item 2.02 (results) | $26.60 |
| Mar 2, 2026 | 8-K Item 2.02 (results) | $23.31 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $23.16 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $17.90 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $12.16 |
| May 8, 2025 | 8-K Item 2.02 (results) | $11.32 |
| Mar 5, 2025 | 8-K Item 2.02 (results) | $13.18 |
| Jan 8, 2025 | 8-K Item 2.02 (results) | $14.13 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $13.70 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on ZYME
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.